CGTX: Cognition Therapeutics Price to Net Income Growth Ratio
Cognition Therapeutics (CGTX) adheres to environmental standards through laboratory safety and office digitalization. Within the scientific community, Cognition Therapeutics (CGTX) is valued for its research into methods for restoring neural connections in Alzheimer's disease. Effective management of grants and patents confirms the asset's potential, which supports the change in the PEG ratio. The value of 0.00 indicates the level of this metric, helping to determine the undervaluation of shares relative to their growth.
Analytical breakdowns for Cognition Therapeutics, Inc. (CGTX)
- current quotes and average value forecast:
- market capitalization information:
- book capitalization data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Capital Cognition Therapeutics|CGTX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Cognition Therapeutics Inc.|CGTX - Company Debts|Debts to Book Value Cognition Therapeutics|CGTX - Company Long-Term Debt|Company Short-Term Indebtedness Cognition Therapeutics|Intermediate Coverage Ratio cogrx.com
- net income and valuation multiples indicators:
CGTX - Net Income|Future Net Profit Cognition Therapeutics|CGTX - P/E Multiple|Future Price to Earnings Multiple cogrx.com|CGTX - PEG Multiple|Company Value to EBITDA Cognition Therapeutics|CGTX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Cognition Therapeutics|CGTX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth cogrx.com|CGTX - Earnings per share growth in current year|Net earnings per share change forecast for next year Cognition Therapeutics
- issuer revenue and sales details:
Fundamental company analysis:CGTX - cogrx.com
The PEG ratio compares a stock's market value with its earnings growth rate, determining the degree of an asset's undervaluation relative to its growth dynamics. Within the stable US legal framework for drug development, Cognition Therapeutics (CGTX) minimizes external risks, making changes in the PEG ratio a key indicator for identifying undervalued "rockets" with high capitalization potential.
Competitors of Cognition Therapeutics
BIIB - Price to Earnings Adjusted for Growth Rate|PEG Multiple NBIX (Neurocrine Biosciences Inc)|Price to Net Income Growth Ratio Regencell Corp|AXSM - Price/Earnings to Growth Ratio|ACAD (acadia-pharm.com) - Growth-Adjusted P/E Ratio|XENE: PEG Multiple|VKTX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple SUPN|CPRX (Catalyst Corp) - Company Value to Earnings Growth Ratio|PEG Multiple DNLI|Growth-Adjusted Market Cap to Net Income harmonybiosciences.com|Price/Earnings to Growth Ratio Biohaven BHVN|Amylyx Pharmaceuticals Inc (AMLX) - Price to Earnings Adjusted for Growth Rate|TRVI - Price/Earnings to Growth Ratio|PRAX (Praxis Corp) - Growth-Adjusted P/E Ratio|AVXL (Anavex Life Sciences) - Price/Earnings to Growth Multiple|ceribell.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple PRTA|ALEC (Alector Therapeutics) - Company Value to Earnings Growth Ratio|PEG Multiple ANNX|OMER (omeros.com) - Growth-Adjusted Payback Ratio|PEG Multiple NGNE (Neurogene Inc.)|acimmune.com (ACIU) - Price to Earnings Adjusted for Growth Rate|VYGR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio NMRA (Neumora)|SCLX: PEG Multiple|Tevogen Bio Inc. (TVGN) - PEG Multiple|Price/Earnings to Growth Ratio Alpha Cognition Inc|inhibikase.com - Market Cap to Earnings and Growth Ratio|PEG Multiple SAVA|ASRT - Price to Earnings Adjusted for Growth Rate|Coya Therapeutics - Price/Earnings to Growth Multiple|PEG Multiple VistaGen Therapeutics, Inc. VTGN|OVID: Price/Earnings to Growth Multiple|acumenpharm.com - Company Value to Earnings Growth Ratio|CRVO: PEG Multiple|ATHE - Growth-Adjusted Market Cap to Net Income|CLNN (Clene Inc) - PEG Multiple|Price/Earnings to Growth Multiple PepGen Corp (PEPG)|Price/Earnings to Growth Ratio Jupiter Neurosciences Inc (JUNS)|Growth-Adjusted Market Cap to Net Income relmada.com|PEG Multiple ANVS (Annovis Bio)|GRCE - Price/Earnings to Growth Multiple|Firefly Neuroscience Inc - PEG Multiple|Price to Net Income Growth Ratio Klotho Neurosciences Inc (KLTO)|NRSN (neurosense-tx.com) - Price/Earnings to Growth Multiple|RVPH: Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple MTVA|Growth-Adjusted P/E Ratio NRXS (NeurAxis Inc.)|Price/Earnings to Growth Ratio Helius Medical (HSDT)|passagebio.com - Growth-Adjusted P/E Ratio|PEG Multiple NEUP (Neuphoria Therapeutics)|minervaneurosciences.com (NERV) - Price to Earnings Adjusted for Growth Rate|ATHA: Price/Earnings to Growth Multiple|ADXN - PEG Multiple|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Cyclerion Therapeutics, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|Price to Earnings Adjusted for Growth Rate Pasithea KTTA|PEG Multiple CRGT|Price/Earnings to Growth Multiple Avenue Therapeutics Inc. ATXI|Price/Earnings to Growth Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Cara Therapeutics Inc (CARA) - Price to Earnings Adjusted for Growth Rate|Chromocell Therapeutics - PEG Multiple|Price to Net Income Growth Ratio Eliem Therapeutics (ELYM)|intracellulartherapies.com (ITCI) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio LBPH|MRNS (Marinus) - PEG Multiple|NKGen Biotech Corp (NKGN) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple NRBO (NeuroBo Pharmaceuticals)|Company Value to Earnings Growth Ratio SAGE|PEG Multiple SNPX (Synaptogenix)|Growth-Adjusted Market Cap to Net Income Trevena Inc. (TRVN)|VIGL - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Anew Medical Inc.|Cerevel Therapeutics (CERE) - Price/Earnings to Growth Ratio
